Malaria pre-exposed volunteers exhibit large breadth of humoral immune responses, with strong variation between individuals, which might compromise vaccine-induced humoral immune response due to natural imprinting.
The structure of the promising malaria blood-stage vaccine candidate antigen PfCyRPA and the characterization of a protective epitope are facilitating research on its essential role in parasite invasion, and will guide future epitope-focused vaccine design.
Molecular biosignatures that identify an inflammatory and potentially adverse reaction to vaccination have been defined in mice, a critical gatekeeper for progression of novel vaccine candidates into humans.
Antibody responses to individual and optimal combinations of P. vivax recombinant proteins in naturally-exposed populations help to identify correlates of protective immunity, and establish a clear path to testing a multicomponent P. vivax vaccine.
In large vaccine trials conducted in dengue-endemic Asia and Latin America, the CYD-TDV tetravalent dengue vaccine shows limited variation in intra-serotype efficacy in the target population for vaccination (>9 years).